Ignite Creation Date:
2024-05-05 @ 11:34 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00087763
Status:
COMPLETED
Last Update Posted:
2006-05-03
First Post:
2004-07-13
Brief Title:
Pegaptanib Sodium on Foveal Thickening in Patients With Exudative Subfoveal Age-Related Macular Degeneration AMD
Sponsor:
Eyetech Pharmaceuticals
Organization:
Eyetech Pharmaceuticals
Study Overview
Official Title:
A Phase II Prospective Randomized Double-Masked Sham-Controlled Dose-Ranging Multi-Center Trial to Assess the Effect of Pegaptanib Sodium on Foveal Thickening in Patients With Exudative Subfoveal Age-Related Macular Degeneration AMD
Status:
COMPLETED
Status Verified Date:
2006-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine if Macugen reduces foveal thickness and improves vision in patients with wet AMD
Detailed Description:
This will be a randomized double-masked controlled dose-ranging multi-center comparative trial in parallel groups Patients will be stratified by clinical center and foveal thickness to be treated either Macugen or a sham injection After 24 weeks all patients will treated with Macugen until the end of the study at 54 weeks
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None